Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
Future Oncol
; 14(6): 553-566, 2018 Mar.
Article
en En
| MEDLINE
| ID: mdl-29460642
ABSTRACT
Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Biliar
/
Carcinoma Hepatocelular
/
Terapia Molecular Dirigida
/
Neoplasias Hepáticas
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos